Artificial intelligence (AI) can help derive meaning from data collected in healthcare to avoid noise and wasted efforts, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Artificial intelligence (AI) can help derive meaning from data collected in healthcare to avoid noise and wasted efforts, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
With more attention being placed on things like social determinants of health, how can AI and machine learning help to turn that information into actionable data?
The burning phrase for 2019 seems to be “social determinants of health” or “social drivers of health,” if you will, and other phrases around that. The initial reaction or the initial action step people take, then, is to get the data, and what they have then is a whole lot of data and they don’t know what to do with it. AI will help to turn that data and derive meaning from it. Which is very important, because if you don’t have that, you end up wasting energy and effort if you say, “well this whole zip code is in a food desert,” and then you treat everybody the same because they live in that zip code. That’s not the right approach. It’s not producing better patient care. It’s producing more costly patient care. So, AI will help to identify which patients are actually at risk.
We take a unique approach and we understand patients with thousands of variables that we see about them to identify who is at risk from a social standpoint, and then we actually roll those up into regions and zip codes and whatnot, and it creates a sense of an understanding about an area, not based upon what we’ve learned about census data or other socially derived data sources, but rather at the individual level and then we roll it up and we get a sense of what’s happening in that region.
So, it’s powerful when you have knowledge coming from that data. Otherwise, it’s not only noise, but it can actually create a lot of wasted effort.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More